Skip to main content
. 2012 Dec 5;32(49):17921–17931. doi: 10.1523/JNEUROSCI.2664-12.2012

Figure 8.

Figure 8.

Alteration of D3R levels in dyskinetic animals treated with l-DOPA or pramipexole. A, 6-OHDA-lesioned animals were treated chronically with 10 mg/kg l-DOPA, 0.3 mg/kg pramipexole, or 1 mg/kg pramipexole and divided into two groups based on the presence (Dys) or absence (Non Dys) of dyskinesia. Striatal lysates from the above-indicated experimental groups were analyzed by Western blot (wb) analysis with D3 antibodies (see Materials and Methods). The same amount of proteins was loaded per lane. Histograms show the quantification of wb experiments after normalization on tubulin levels (CTRL vs pramipexole 0.3 mg/kg Non Dys, **p < 0.01; 6-OHDA vs pramipexole 0.3 mg/kg Non Dys, #p < 0.05; pramipexole 1 mg/kg Non Dys vs pramipexole 1 mg/kg Dys ##p < 0.01; pramipexole 0.3 mg/kg Non Dys vs pramipexole 1 mg/kg Dys ##p < 0.01; l-DOPA Non Dys vs l-DOPA Dys, #p < 0.05). B, Bar graph compares the NMDAR/AMPAR ratio recorded in vitro from dyskinetic animals after chronic treatment with the high dose of pramipexole, with or without a prolonged incubation of the D1 antagonist SCH23390 (n = 6 pramipexole 1 mg/kg vs n = 5 pramipexole 1 mg/kg plus SCH23390, **p < 0.01).